Literature DB >> 2227249

Class II (HLA-DR, -DP, and -DO) antigens on intestinal epithelia in ulcerative colitis, Crohn's disease, colorectal cancer and normal small intestine.

Y Horie1, M Chiba, M Iizuka, O Masamune.   

Abstract

Class II antigens in involved colonic epithelia of ulcerative colitis (UC), Crohn's disease (CD), colorectal cancer, and epithelia of normal small intestine were investigated using an immunoperoxidase method. Ten normal colonic mucosa served as normal controls. Ten specimens were studied for each group. Normal colonic epithelia did not express class II antigens. In colonic diseases; (1) with regard to the frequency and extent of class II antigens on epithelia. HLA-DR antigens were the most highly and greatly expressed, followed by HLA-DP and then HLA-DQ antigens. (2) The extent of HLA-DR and -DP, but not HLA-DQ, expression on epithelia of UC and colorectal cancer seemed to be positively correlated with the degree of mononuclear cell infiltration in the lesion. (3) The extent of class II antigen expression on colonic epithelia in CD was not related to the degree of mononuclear cell infiltration in the lesion. (4) The extent of HLA-DR and -DP expression on epithelia of colorectal cancer seemed to be positively correlated with increasing undifferentiation. In the normal small intestine, where HLA-DR antigens were physiologically expressed on epithelia. HLA-DQ antigens were not expressed. The heterogeneity among colonic diseases, and between the physiological and pathological status, may reflect differences in immunoregulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227249     DOI: 10.1007/bf02779357

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  39 in total

1.  The value of rectal biopsy in the diagnosis of ulcerative colitis.

Authors:  S G MATTS
Journal:  Q J Med       Date:  1961-10

2.  HLA-DR antigen expression in macroscopically uninvolved areas of intestinal epithelia in Crohn's disease.

Authors:  M Chiba; M Iizuka; Y Horie; K Igarashi; O Masamune
Journal:  Gastroenterol Jpn       Date:  1989-08

3.  Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.

Authors:  Y X Chen; R L Evans; M S Pollack; L L Lanier; J H Phillips; C Rousso; N L Warner; F M Brodsky
Journal:  Hum Immunol       Date:  1984-08       Impact factor: 2.850

4.  Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease.

Authors:  W S Selby; G Janossy; D Y Mason; D P Jewell
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

5.  Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer.

Authors:  F Momburg; T Degener; E Bacchus; G Moldenhauer; G J Hämmerling; P Möller
Journal:  Int J Cancer       Date:  1986-02-15       Impact factor: 7.396

6.  Expression of HLA-DR antigens in inflammatory bowel disease mucosa: role of intestinal lamina propria mononuclear cell-derived interferon gamma.

Authors:  O Y Qin; M el-Youssef; B Yen-Lieberman; W Sapatnekar; K R Youngman; K Kusugami; C Fiocchi
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

7.  Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma.

Authors:  R Schwartz; F Momburg; G Moldenhauer; B Dörken; V Schirrmacher
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

8.  Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.

Authors:  S Carrel; A Schmidt-Kessen; L Giuffrè
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

9.  Induction of HLA-DC/DS (LEU 10) antigen expression by human precursor B cell lines.

Authors:  C Y Wang; A Al-Katib; C L Lane; B Koziner; S M Fu
Journal:  J Exp Med       Date:  1983-11-01       Impact factor: 14.307

10.  Is heterogeneous expression of HLA-dr antigens and CEA along with DNA-profile variations evidence of phenotypic instability and clonal proliferation in human large bowel carcinomas?

Authors:  T O Rognum; P Brandtzaeg; E Thorud
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640

View more
  7 in total

1.  Expression of MHC class II antigens (HLA-DR, -DP, and -DQ) on human gastric epithelium.

Authors:  N Ishii; M Chiba; M Iizuka; H Watanabe; T Ishioka; O Masamune
Journal:  Gastroenterol Jpn       Date:  1992-02

2.  Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry.

Authors:  Y Fujimura; R Kamoi; M Iida
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

3.  Differential major histocompatibility complex class II locus expression on human laryngeal epithelium.

Authors:  L E Rees; O Ayoub; K Haverson; M A Birchall; M Bailey
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

4.  Expression of HLA-DR antigens on colonic epithelium around lymph follicles. An anomalous expression in Crohn's disease.

Authors:  M Chiba; M Iizuka; Y Horie; N Ishii; O Masamune
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

5.  HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.

Authors:  Margaret R Dunne; Adriana J Michielsen; Katie E O'Sullivan; Mary Clare Cathcart; Ronan Feighery; Brendan Doyle; Jenny A Watson; Naoimh J O'Farrell; Narayanasamy Ravi; Elaine Kay; John V Reynolds; Elizabeth J Ryan; Jacintha O'Sullivan
Journal:  Cancer Immunol Immunother       Date:  2017-03-18       Impact factor: 6.968

6.  HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression.

Authors:  K Matsushita; T Takenouchi; S Kobayashi; H Hayashi; K Okuyama; T Ochiai; A Mikata; K Isono
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.